Centre Flags Alarming Rise in Fake GST Firms: Rs 58,772 Crore Detected in FY 2024-25



Quick Summary
The Indian government has reported a significant increase in Goods and Services Tax (GST) evasion, primarily through the use of fake invoicing and dormant companies, including inactive pharmaceutical firms. In the financial year 2024-25 alone, over Rs 58,772 crore was detected in such fraudulent activities. In response, authorities have introduced several technology-driven measures and stricter compliance protocols to prevent fake registrations and curb Input Tax Credit (ITC) fraud.

The Government of India has confirmed a sharp rise in GST evasion through fake invoicing, including schemes involving sleeping modules and inactive pharmaceutical firms used as fronts for fraud. The details were shared by Minister of State for Finance Shri Pankaj Chaudhary in a written reply to an unstarred question in the Rajya Sabha.

Fake GST Firms Surge: Rs 58,772 Crore Detected

Over 55,000 Fake Invoicing Cases Detected in Three Years

According to Central GST authorities, fake invoicing and ITC fraud cases have surged in recent years. Data shows:

  • 2022-23: 7,231 cases involving Rs 24,140 crore
  • 2023-24: 9,190 cases involving Rs 36,374 crore
  • 2024-25: 15,283 cases involving Rs 58,772 crore
  • 2025-26 (up to Oct 2025): 24,109 cases involving Rs 41,664 crore

The figures reveal a significant increase in both the number of cases and the scale of detection, highlighting how fraud networks continue to exploit loopholes using dormant firms, bogus entities, and fake GST registrations.

Pharmaceutical Firms Also Used as Fake Fronts

The Ministry acknowledged that sleeping or inactive pharmaceutical companies were also used to generate fake invoices. The number of such pharma-related ITC fraud cases includes:

  • 2022-23: 3 cases (Rs 31.71 crore)
  • 2023-24: 0 cases
  • 2024-25: 2 cases (Rs 5 crore)
  • 2025-26 (up to Oct 2025): 2 cases (Rs 7.25 crore)

Although fewer in number, officials consider these cases particularly sensitive because fraudulent pharma units can pose both fiscal and public-health risks.

Government Rolls Out Stringent Measures to Block Fake Registrations

To curb the misuse of dormant firms and prevent fraudulent ITC claims, the government has introduced a series of technology-driven and compliance-focused measures. These include:

  • Mandatory GSTR-1 vs GSTR-2B invoice matching
  • Restriction on filing GSTR-1 without filing GSTR-3B
  • Mandatory e-invoicing for B2B transactions above Rs 5 crore turnover
  • OTP-based PAN verification and risk-based Aadhaar biometric authentication
  • Mandatory physical verification in high-risk cases, even after Aadhaar validation
  • Requirement to furnish valid bank account details within 30 days of registration
  • Geo-tagging of business premises for new GST registrations
  • Automatic suspension of non-compliant GSTINs under Rule 21A
  • System-generated notices (DRC-01B/01C) under Rules 88C/88D
  • Introduction of the Invoice Management System (IMS) to help taxpayers verify and accept supplier invoices
  • Nationwide special drives conducted in 2023 and 2024 to identify and cancel fake registrations

The government also emphasized that fraudulent ITC availment without invoice is now a cognizable and non-bailable offence, and beneficiaries of such frauds are liable for penalties.

Crackdown Intensifies as Cases Continue to Rise

The Ministry's data suggests that despite sustained enforcement efforts, GST evasion networks are expanding rapidly, especially through dummy entities and dormant firms. Officials believe that enhanced digitization, stricter registration protocols, and targeted verification will help curb large-scale ITC fraud as authorities continue to intensify surveillance and coordination across states.

Official copy of the data has been attached

FAQ :

The main concern is the alarming rise in GST evasion through fake invoicing and the exploitation of dormant or inactive companies, including pharmaceutical firms, to commit fraud.

In the financial year 2024-25, a total of Rs 58,772 crore was detected in cases involving fake GST firms and invoicing.

Yes, the government has acknowledged that sleeping or inactive pharmaceutical companies have been used to generate fake invoices and commit Input Tax Credit (ITC) fraud.

The government has implemented technology-driven measures such as mandatory invoice matching, OTP-based PAN verification, Aadhaar biometric authentication, physical verification in high-risk cases, and geo-tagging of business premises.

Yes, fraudulent Input Tax Credit (ITC) availment without an invoice is now a cognizable and non-bailable offence, with penalties applicable to beneficiaries.

The number of fake invoicing cases and the amount detected have surged significantly. For instance, cases rose from 7,231 involving Rs 24,140 crore in 2022-23 to 15,283 involving Rs 58,772 crore in 2024-25.




News posted by

Finance news reporter covering taxation, GST, income tax, business compliance, and economy updates. I simplify complex financial topics into easy-to-understand articles for professionals, taxpayers, and business owners on leading finance and tax platforms.

Click here to Login and post comments    OR



More »


Popular News





CCI Pro